Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Subscribe To Our Newsletter & Stay Updated
